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The heterozygous Pro250Arg substitution mutation in ﬁbroblast growth factor receptor 3 (FGFR3), which
increases ligand-dependent signalling, is the most common genetic cause of craniosynostosis in humans
and deﬁnes Muenke syndrome. Since FGF signalling plays dosage-sensitive roles in the differentiation of
the auditory sensory epithelium, we evaluated hearing in a large group of Muenke syndrome subjects, as
well as in the corresponding mouse model (Fgfr3
P244R). The Muenke syndrome cohort showed signiﬁcant,
but incompletely penetrant, predominantly low-frequency sensorineural hearing loss, and the Fgfr3
P244R
mice showed dominant, fully penetrant hearing loss that was more severe than that in Muenke syndrome
individuals, but had the same pattern of relative high-frequency sparing. The mouse hearing loss correlated
with an alteration in the fate of supporting cells (Deiters’-to-pillar cells) along the entire length of the cochlear
duct, with the most extreme abnormalities found at the apical or low-frequency end. In addition, there was
excess outer hair cell development in the apical region. We conclude that low-frequency sensorineural hear-
ing loss is a characteristic feature of Muenke syndrome and that the genetically equivalent mouse provides
an excellent model that could be useful in testing hearing loss therapies aimed at manipulating the levels of
FGF signalling in the inner ear.
INTRODUCTION
The auditory sensory epithelium, the organ of Corti, is located
along the length of the basilar membrane in the spiral cochlear
duct of the inner ear. In humans and mice, the hearing organ has
four rows of sensory hair cells comprising a single row of inner
hair cells, which transduce most of the auditory information to
the brain, and three rows of outer hair cells, which play a critical
role in amplifying and modulating the response of the inner hair
cells to sound. Each type of hair cell has an associated support
cell; phalangeal cells underlie inner hair cells, and Deiters’ cells
underlie outer hair cells. Another supporting cell type, the pillar
cell, separates the rows of inner and outer hair cells along with
their corresponding supporting cells. In normal ears, two pillar
cells form a triangular space (the tunnel of Corti) and play a role
in regulating the stiffness of the basilar membrane upon which
the organ of Corti vibrates. The sensory tissue is relatively
narrow at the base of the cochlear duct, where it emerges
from the vestibular portion of the inner ear, and wider at
the apical end of the cochlear duct, contributing to the
basal-to-apical gradient of high-to-low frequency sensitivity to
sound (1,2).
Fibroblast growth factor (FGF) signalling is required for the
normal induction, patterning and morphogenesis of the inner
ear epithelium, as well as for the differentiation of cell types
within the organ of Corti (2–4). In particular, FGF20 and
Fgfr1 (both expressed in the prospective sensory region) are
required for sensory hair cell differentiation (5,6) and Fgf8
(expressed in developing inner hair cells) and Fgfr3
(expressed in developing pillar and Deiters’ cells, and for a
time in developing outer hair cells) are required for pillar
cell differentiation (7–12). Over-activation of FGF signalling
also affects cochlear sensory development. Electroporation of
Fgf8 or application of FGF2 or FGF17 to cochlear cultures
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mutants, in which a negative regulator of FGF signalling
expressed prominently in Deiters’ cells is absent, show a
Deiters’ cell-to-pillar cell fate change resulting in excess
pillar cell development (14). Interestingly, both Fgfr3 and
Spry2 null cochleae also show supernumerary outer hair cell
development (9,11,14). Both of these mouse mutants are
hearing impaired, and the Spry2 null excess pillar cell and
deafness phenotypes, but not the excess outer hair cell pheno-
type, are rescued by removing a single copy of Fgf8 (14).
Thus, FGF8 is the likely ligand for ﬁbroblast growth factor
receptor 3 (FGFR3) in pillar cell differentiation, and the
level of FGF signalling involved in the process appears to
be regulated within a very tight range.
FGF receptor mutations that lead to increased FGF signalling
are frequent in humans, with craniosynostosis (premature fusion
of the cranial sutures) and short stature being the most common
skeletalphenotypes(15,16).Muenkesyndrome(OMIM602849)
is caused by a heterozygous 749C.G transversion in FGFR3,
which changes proline 250 to arginine (17,18). This is the most
common individual mutation that occurs in a craniosynostosis
syndrome(19),andseveralreportsindicatethatitcanbevariably
associated with sensorineural hearing loss (HL) (20–24). In in
vitro assays of the FGFR3c spliceform, the proline to arginine
substitution, located in the linker between the extracellular IgII
and IgIII domains of the receptor, resulted in signiﬁcantly
enhanced binding to two of nine tested FGFs, FGF2 and FGF9
(25). These act as physiological ligands of FGFR3c (26), and
Fgf9, in particular, is expressed in the developing cochlear
duct (27). Collectively, these observations, together with the
Spry2 null mouse phenotype, suggested that Muenke syndrome
patients and a mouse model of the Muenke syndrome mutation
(28) should undergo comprehensive auditory phenotyping.
We report here that a sample of 37 subjects with Muenke syn-
drome show signiﬁcant, predominantly low-frequency hearing
loss. Muenke model mice evaluated in four genetic backgrounds
have dominant hearing loss that is more severe than that in
Muenke syndrome patients,but have the same patternof relative
high-frequency sparing, with variation between strains with
respect to the extent of sparing. Similarly to Spry2 null mice,
the Muenke model mice show excess pillar cell development
at the expense of Deiters’ cell development along the entire
length of the cochlear duct, with the most extreme abnormalities
occurring apically, andexcessouter haircell development that is
conﬁned to the apical region. All phenotypes are intensiﬁed in
homozygotes relative to heterozygotes. Surprisingly, we found
that hearing loss was not rescued by removal of a single copy
of either Fgf8 or Fgf9 or both. We conclude that low-frequency
sensorineural hearing loss is a characteristic feature of Muenke
syndrome and that the genetically equivalent mouse provides
an excellent model of this aspect of the phenotype.
RESULTS
Muenke syndrome patients have mild low-frequency
sensorineural hearing loss
The largest previous study of hearing in Muenke syndrome
combined data on 18 subjects tested at four different facilities
(20). To determine the characteristics and penetrance of
hearing loss in a large cohort of individuals with Muenke syn-
drome seen at a single facility, we measured air- and bone-
conducted pure-tone audiometry thresholds in 37 heterozy-
gotes for the FGFR3 P250R mutation (Fig. 1A). In the
group as a whole, signiﬁcant mild hearing loss was present,
which was more marked at low frequencies (0.25–1 kHz;
32–35 dB HL [decibels hearing level]) than at high frequen-
cies (2–8 kHz; 22–28 dB HL) (Fig. 1A). After excluding
ears for which masked bone conduction could not be measured
and/or there was evidence of middle ear disease (see Materials
and Methods), we obtained a cleaned audiometric dataset for
41 ears from 30 different subjects (Fig. 1B). While the differ-
ence between the air and bone conduction was reduced at all
frequencies compared with the original dataset, the mean
thresholds measured for bone conduction remained virtually
unchanged, ranging from 25 dB HL at 1 kHz to 10 dB HL at
4 kHz (Fig. 1B). This indicates that the hearing loss in
Muenke syndrome is largely sensorineural. No signiﬁcant
sex difference was observed (data not shown). Estimation of
the penetrance of signiﬁcant sensorineural hearing loss
(deﬁned as  20 dB bone conduction) in this cleaned dataset
conﬁrmed that it is signiﬁcantly more severe at lower frequen-
cies, with 28 of 41 ears (68%) showing hearing loss at 1 kHz
but only nine of 41 ears (22%) at 4 kHz (P ¼ 4.8   10
25,
Fisher’s exact test, two-tailed). Nine subjects (22%) in our
cohort have been ﬁtted with hearing aids owing to the severity
of their hearing loss.
Muenke model mice are moderately hearing impaired,
and hearing loss is more severe at low frequencies than at
high frequencies
We have reported separately (28) the construction of a precise
molecular mimic of the Muenke syndrome mutation in mice
(Fgfr3
P244R). Muenke model mice have craniofacial phenotypes
that vary in penetrance and expressivity depending on genetic
background, but do not include obvious middle ear anomalies.
Toassesshearinginthismodel,wemeasuredauditorybrainstem
response (ABR) thresholds to click (broadband low fre-
quency), 8, 16 and 32 kHz tone-pip stimuli in wild-type, hetero-
zygous and homozygous Fgfr3
P244R mice in four different
genetic backgrounds (Fig. 2). As expected, wild-type mice in
each background had a range of normal auditory thresholds
(29,30), with the lowest thresholds occurring at 16 kHz in all
Figure 1. Individuals heterozygous for the Muenke syndrome mutation have
low-frequency sensorineural hearing loss. (A) hearing loss measured in
dB HL+SE and plotted as a function of frequency in kHz for 37 subjects
with the FGFR3 P250R mutation. Results of air and bone conduction tests are
plotted separately using white and grey symbols, respectively. (B) Cleaned
dataset, comprising a total of 41 ears from 30 subjects for which paired sets
of air and bone conduction data were available, and excluding ears showing
evidence of compromise in middle ear function on tympanometry.
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open symbols). In contrast, all heterozygous mice, regardless
of genetic background, had increased auditory thresholds (by
8–56 dB, depending on strain and stimulus) at all test points
(Fig. 2, grey symbols) and homozygotes exhibited a further
5–9 dB decrement in hearing (16–62 dB above wild-type;
Fig. 2, black symbols). BALB/c homozygotes could not be eval-
uated as we recovered too few live animals. Heterozygote and
homozygote ABR thresholds were signiﬁcantly elevated relative
to wild-type at all test frequencies, and in all strain backgrounds
(P , 0.0001) except at 32 kHz in the C57BL/6 background. In
allcases,homozygousthresholdsweregreaterthanheterozygous
thresholds,and inthe caseofthe click response inallthree back-
grounds that could be evaluated, and at all frequencies tested in
the CBA/Ca strain, the differences were statistically signiﬁcant
(0.0024 , P , 0.039). The small magnitudes not withstanding,
these differences reﬂect 2–3-fold differences in hearing sensi-
tivity. Unlike the craniofacial phenotypes (28), there was no
effect of sex on the hearing loss phenotype (data not shown).
Hearing loss (average heterozygous or homozygous minus
wild-type means) in all strains was less severe at 32 kHz
than at lower frequencies (Fig. 3). These differences were
highly signiﬁcant (0.0001 , P , 0.0018) in the C57BL/6,
129S6 and BALB/c backgrounds, but less so in the CBA/Ca
background (0.017 , P , 0.048), and not signiﬁcant for the
speciﬁc comparison of the CBA/Ca homozygotes at 32 and
16 kHz (P ¼ 0.11). Furthermore, there was also relative
sparing of hearing loss at 16 kHz in the C57BL/6 background,
but this may be due to the relatively poor hearing of the wild-
type strain at 16 kHz rather than to an effect of the mutation.
These data show that the Muenke syndrome model has hearing
loss that is more severe, but of a similar pattern (low
frequency.high frequency) to that found in Muenke syn-
drome subjects (compare Figs 1 and 3). In addition, expressiv-
ity of the hearing loss phenotype varies with genetic
background; it is more severe on the 129S6 and C57BL/6
backgrounds than on the CBA/Ca and BALB/c backgrounds.
Finally, the hearing loss is Fgfr3
P244R dosage sensitive; homo-
zygotes are more severely affected than heterozygotes.
Muenke model mice have extra pillar cells and fewer
Deiters’ cells in the organ of Corti
In mice, both inhibition of Fgfr3 function and excessive FGF
signalling, mediated by the loss of Spry2, lead to hearing loss
together with altered relative numbers of pillar and Deiters’
cells (see Introduction); thus we suspected that deafness in
the Muenke syndrome model animals might also be a conse-
quence of aberrant organ of Corti development. Histological
comparison of wild-type inner ears with those of heterozygous
and homozygous animals in the 129S6 background suggests
that this is indeed the case (Fig. 4). Cross-sections taken
through the wild-type organ of Corti show three outer hair
cells supported by three Deiters’ cells at all basal to apical
levels of the cochlea. Two pillar cells separate the outer hair
cell/Deiters’cellsfromtheinnerhaircell(Fig.4A–A00).Incon-
trast, heterozygous and homozygous Fgfr3
P244R mutants
showed three outer hair cells, but only one Deiters’ cell and
four pillar cells in basal and mid-basal cochlear cross-sections.
In these mutants, inner hair cell numbers were normal (Fig. 4B,
B0, C and C0). Apical cross-sections taken through the cochlear
ducts of heterozygotes had the same cellular pattern, but
occasionally showed a fourth outer hair cell, with or without
an additional Deiters’ cell (Fig. 4B00). Apical cross-sections
taken through the cochlear ducts of homozygotes sometimes
showed as many as ﬁve pillar cells, one or two Deiters’ cells
and often showed four or more outer hair cells (Fig. 4C00).
These data demonstrate Fgfr3 dose-dependent abnormalities
of organ of Corti differentiation that are more severe at apical
(low frequency) than basal (high frequency) regions, consistent
with the hearing loss in Muenke model mice.
Muenke model mice have extra outer hair cell in the apical
region of the cochlear duct
In addition to its effects on pillar and Deiters’ cell differen-
tiation, changes in signalling through FGFR3 also affect
Figure 2. Dominant hearing loss in Fgfr3
P244R mice on four genetic back-
grounds. ABR thresholds in decibels sound pressure level (dB SPL) +SE
were measured for click (C), 8, 16 and 32 kHz tone-pip stimuli in wild-type,
heterozygous and homozygous mice inbred on four genetic backgrounds.
Open circles indicate wild-type, grey circles indicate heterozygotes and
black circles indicate homozygotes.
Figure 3. Sparing of high-frequency hearing in Fgfr3
P244R mice. Mean differ-
ence in dB SPL+SE between heterozygous or homozygous and wild-type
mice is shown for each stimulus and genetic background. Symbols are the
same as for Figure 2.
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ous extra row of outer hair cells in the apical 60–67% of the
cochlear duct (9,11), and Spry2 null mice have patchy extra
outer hair cell rows that are more continuous at apical cochlear
regions (14). To better assess outer hair cell development
along the length of the Fgfr3
P244R cochlear duct, we stained
surface preparations of the P0–P5 129S6-derived organ of
Corti with Alexa-488-phalloidin and visualized hair cell
stereocilia (Fig. 5). Wild-type P3 epithelia had one row of
inner hair cells and three rows of outer hair cells at basal,
mid and apical levels of the cochlear duct (Fig. 5A, B, B0
and B00). Only the most apical regions of wild-type epithelia
showed small patches of extra outer hair cells (Fig. 5B00). As
expected from the adult histology, we found longer stretches
of extra outer hair cells in both Fgfr3
P244R heterozyotes and
homozygotes. In heterozygotes, the extra outer hair cells were
seen in the middle and apical domains of the cochlea and
were discontinuous (Fig. 5C, C0 and C00). In homozygotes, the
Figure 4. Extra pillar cells and fewer Deiters’ cells at all levels in Muenke model cochlear ducts. HþE stained sections taken through basal (A–C), mid-basal
(A0–C0) and apical (A00–C00) turns of the cochlear duct of 4–5-week-old wild-type (A and A0), heterozygous (B–B00) and homozygous (C–C00)
129S6-background mice. dc, Deiters’ cells; ihc, inner hair cells; ohc, outer hair cells; pc, pillar cells.
Figure 5. Extra outer hair cells at mid and basal regions of Muenke model cochlear ducts. Phalloidin-stained P3 cochlear surface preparations. (A) Whole
cochlea illustrating the apical area (white line) in which the most complete rows of supernumerary hair cells could be found in Fgfr3
P244R cochleae. Basal
(B–D), mid (B0–D0) and apical (B00–D00) segments of wild-type (B–B00), heterozygous (C–C00) and homozygous (D–D00) cochlear ducts. i, inner hair cells;
o, outer hair cells. Circled region in B00 shows the only extra outer hair cells found in an entire wild-type duct.
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approximately the apical 25% of the cochlear duct (Fig. 5D,
D0 and D00). Thus, signalling through FGFR3 induces apical
outer hair cell development in a dose-dependent fashion.
Reducing the copy number of Fgf8 or Fgf9 or both does not
rescue Fgfr3
p244r hearing loss
The hearing loss and cochlear cytoarchitecture found in
Fgfr3
P244R/þ mice appeared similar to that described for
Spry2
2/2 mice, suggesting that reducing the levels of FGF8
signalling might rescue Fgfr3
P244R/þ hearing loss, as is true
for Spry2
2/2 mutants (14). We therefore crossed BALB/
c-Fgfr3
P244R/þ mice, which showed the mildest hearing loss,
to Fgf8
þ/2 mice and measured ABR thresholds in animals
of each possible genotype. All Fgfr3
P244R/þ animals in this
hybrid background were hearing impaired, regardless of Fgf8
gene dosage (Supplementary Material, Fig. S1). Since the
mutantFGFR3P250Rproteinexhibitsalargeincreaseinafﬁnity
for FGF9 relative to the wild-type receptor (25), and Fgf9 is
expressed in the cochlear duct, albeit rather far from the devel-
oping organ of Corti (27), we also tried reducing the dose of
Fgf9 alone, or in combination with Fgf8.A sw i t ht h eFgf8
þ/2
allele alone, neither Fgf9
þ/2 nor the combination of Fgf8
þ/2
and Fgf9
þ/2 was able to rescue Fgfr3
P244R/þ hearing loss
(Supplementary Material, Fig. S1).
DISCUSSION
Our data indicate that Fgfr3
P244R/þ mice, a model of Muenke
syndrome, have dominant, fully penetrant hearing loss that is
more severe at low than at high frequencies. This is qualitat-
ively similar, but more severe, than the hearing loss that we
have documented in the largest audiological study of subjects
with the Muenke syndrome mutation reported to date and is
consistent with other recent work (20,22). These ﬁndings
emphasize the need to ensure that all individuals heterozygous
for the P250R mutation in FGFR3 are offered audiological
testing and appropriate management for hearing loss. The
differences in the absolute and relative magnitudes of high-
frequency versus low-frequency hearing loss between the
different mouse genetic backgrounds suggest that the variabil-
ity in auditory phenotypes seen in the Muenke syndrome
patients has, in part, a genetic basis.
Our results suggest that other individuals and mouse models
bearing activating FGFR3 mutations might also present with
sensorineural hearing loss.Indeed, somestudiesofachondropla-
sia patients(thegreatmajorityofwhomareheterozygousforthe
FGFR3 G380R substitution) report sensorineural hearing loss
(31–33), and the corresponding mouse model (Fgfr3
G374R/þ)
could be tested for hearing (34). Many of the other common
syndromes caused by FGFR3 activation are neonatal lethal
in humans (15,16); however, the Fgfr3
S365C/þ mouse strain,
which models thanatophoric dysplasia type I, is viable (35)
and could be evaluated for hearing loss and cochlear dysplasia.
In humans, autosomal dominant non-syndromic low-frequency
sensorineural hearing loss is relatively unusual. Some such indi-
viduals have mutationsinDIAPH1orWFS1 (36–39),but others
are unexplained, and our data suggest that FGFR3 should be
considered as a candidate for these other cases. Interestingly, a
putative dominant negative mutation in FGFR3, R621H,
appears associated with a reversed pattern of hearing loss to
that documented for P250R, with hearing at higher frequencies
more severely affected (40).
Our histological study of Fgfr3
P244R cochleae revealed two
patterningdefectsoftheorganofCorti,oneinvolvingsupporting
cells and the other involving sensory cells. All cochlear levels
showed at least two excess pillar cells at the expense of
Deiters’ cells, and this phenotype was most severe in the
apical region, where three or more ectopic pillar cells formed
at the expense of Deiter’s cell. In addition, we found supernu-
merary outer hair cell development that was conﬁned to the
apicalregion.Thesecellulardefectsaresimilarto,butsomewhat
more severe, than those reported for hearing-impaired Spry2
2/2
mice, in which FGF signalling is increased by relief of negative
regulation (14). Since Spry2
2/2 hearing loss and support cell
phenotypes, but not the outer hair cell phenotype, are rescued
when an Fgf8 null allele is introduced, it is likely that the
support cell abnormalities seen in Fgfr3
P244R mice are the
major cause of their hearing loss. In addition, the increased
severity of supporting cell mispatterning at the apical end of
the Fgfr3
P244R cochlear duct is consistent with the greater
elevation of low-frequency relative to high-frequency ABR
thresholds.
Both cytoarchitectural defects seen in Fgfr3
P244R mice are
conﬁned to cells that normally express Fgfr3 during organ of
Cortidevelopment.Fgfr3expressioninitiatesatE15.5inthepre-
cursors of pillar, Deiters’ and outer hair cells, turning on in a
base-to-apex wave. Expression is subsequently restricted to
pillar and Deiters’ cells at P0, and ﬁnally to pillar cells only by
P7 (9,14). Fgfr3 null or Fgf8 otic conditional null mice have
defects in pillar cell differentiation (9–12), suggesting that
FGF8, which is expressed from about E15.5 in the prospective
inner hair cell, signals to the two closest FGFR3-expressing
cells to differentiate as pillar cells. Presumably the FGF8
signal is too low to activate the FGFR3 receptors expressed by
more lateral cells, which differentiate as Deiters’ cells and
then turn off Fgfr3. Spry2, which encodes an inhibitor of FGF
signalling,isinitially expressedsimilarly toFgfr3inprospective
pillar cells, Deiters’ cells and outer hair cells, but is restricted to
Deiters’ cells by P5. Thus, in its absence, FGF8-dependent sig-
nalling occurs normally in prospective pillar cells, but is likely
increased in the prospective Deiters’ cell most proximal to the
inner hair cell, causing it to differentiate as a pillar cell. There-
fore, removal of one copy of Fgf8 from the Spry2 null restores
to some extent the balance of signalling back towards the wild-
type differentiation pattern (14). In the Muenke model organ of
Corti, we found that at least two prospective Deiters’ cells adopt
the pillar cell fate. This could reﬂect a higher level of signalling
induced by the P244R mutation in FGFR3 relative to that
induced by the wild-type ligand/receptor pair in the absence of
Spry2. Indeed, in contrast to the Spry2 null, Muenke model
hearing loss was not rescued by removal of a single copy of
Fgf8. Thus, a further reduction in FGF8 and/or FGFR3 levels
may be necessary to achieve rescue. Alternatively or in addition
to FGF8, the mutant FGFR3 P244R may be activated by
additional ligands. Removal of one copy of FGF9, which has a
high afﬁnity for FGFR3c in vitro, did not rescue the auditory
phenotype, suggesting that it may not contribute signiﬁcantly
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FGFs in the FGF9 family are FGF16 and FGF20 (41), both
of which are expressed in the cochlea (5,42). The latter, by
virtue of its expression in the prosensory region (5), is a
particularly attractive candidate for activation of signalling
through FGFR3 P244R, though its expression may terminate
too early to contribute to the excess pillar cell phenotype of
Muenke model cochleae. A ﬁnal consideration in seeking to
explain the differences between the Muenke model and the
Spry2 null cochlea is the relative timing of expression of inhibi-
tors of FGF signalling, some of which are transcriptional targets
of FGF signalling. SPRY2 acts as a feedback inhibitor in some
situations (43), but this does not appear to be the case in the
organ of Corti, where Spry2 is unaffected by the loss of Fgfr3
(9). Spry1 and Dusp6 (Mkp3) are also expressed in the develop-
ing organ of Corti (14,44), eventually appearing to be speciﬁc to
pillar cells, but their responses to loss of Fgfr3 or Spry2 are
unknown. Thus, a developmental study of the Muenke model,
focusing on indicators and inhibitors of FGF signalling, as
well as markers of cellular differentiation, should help to eluci-
date precisely which cells experience increased FGF signalling
a n dw h e ni to c c u r sr e l a t i v et oFgf gene expression.
It was notable that Fgfr3
P244R cochleae developed super-
numerary outer hair cells in the apical region. This phenotype
was also more pronounced than in Spry2
2/2 mutants, in which
excess outer hair cell development is patchy, but was less
extensive than in Fgfr3
2/2 mutants, which have excess
outer hair cell (and Deiters’ cell) development along the
apical 60–67% of the cochlea (9,11). How can both increases
and decreases in FGF signalling cause additional outer hair
cell development? Hayashi and colleagues proposed that
Fgfr3
2/2 mice have extra outer hair cells because in the
absence of cells expressing FGFR3 to bind the available
FGF8, FGF8 is able to diffuse more laterally across the
sensory epithelium to activate FGFR1 (9), which is normally
stimulated by FGF20 to specify hair cell development (5,6).
In addition, Shim and colleagues proposed that Spry2
2/2
mice have extra hair cells, not due to an increase in FGF8 sig-
nalling through FGFR3, but rather by increased signalling
through FGFR1. Their observation that an Fgf8 null allele
rescues the ectopic pillar cell phenotype of Spry2
2/2
mutants, but not the ectopic outer hair cell phenotype, supports
this interpretation (14). To explain the excess outer hair cell
phenotype in Meunke model mice, in which FGFR3, rather
than FGFR1, activity is increased, we propose that the
FGFR3 P244R mutant protein has an increased afﬁnity for
FGF20 (as it does for the structurally related FGF9) (25,41)
and that this signalling event increases the extent of the pro-
sensory domain that can differentiate as hair cells. As the
base-to-apex wave of Fgf20 expression initiates 2 days
before that of Fgfr3 and quickly recedes, it may be that the
Fgfr3
P244R apex is the only area that has abnormally high
levels of FGF20-stimulated signalling, and thus is the only
region that develops extra hair cells. It will be interesting to
determine the timing of the appearance of the supernumerary
hair cells relative to Fgf20 expression dynamics and to deter-
mine whether removal of one copy of Fgf20 will rescue the
Fgfr3
P244R outer hair cell phenotype.
In summary, we have shown that a mouse model of the
Muenke syndrome mutation has hearing loss similar to that
found in Muenke syndrome patients and that hearing loss
correlates with abnormalities of organ of Corti differentiation,
which are similar to those seen when a negative regulator of
FGF signalling is removed. This mouse model should be
useful in testing hearing loss therapies aimed at manipulating
the levels of FGF signalling in the inner ear.
MATERIALS AND METHODS
Ascertainment and audiological assessment of subjects
with Muenke syndrome
Audiological testing was performed on 41 individuals (includ-
ing 14 affected parents) from 23 different families with
Muenke syndrome presenting to the Oxford Craniofacial
Unit. Heterozygosity for the 749C.G mutation was demon-
strated by either NciIo rBanI digestion, or DNA sequencing,
of the human FGFR3 exon 7 amplimer (45).
Age-appropriate audiometry and tympanometry were
performed on each patient according to British Society of
Audiology recommended procedures. Audiometric tests were
obtained in a double-walled soundproof test room (to ISO
8253-1 standards), using either a Grason–Stadler Inc 61
audiometer or a Kamplex AD27 audiometer (both machines
comply with the BSEN 60645 part 1 speciﬁcation for audio-
meters and are calibrated to ISO 389 series). Four children
unable to perform pure-tone audiometry using headphones
were excluded. For the remaining 37 subjects, separate
measurements of air conduction in each ear (0.25–8 kHz),
and unmasked bone conduction (0.5–4 kHz), were obtained
(in one subject with normal hearing, bone conduction was
not obtained but was assumed equal to air conduction in the
better hearing ear). If the difference between bone conduction
and air conduction for both ears was  10 dB at all frequencies
for either ear, then the ﬁgure for bone conduction was
attributed to both ears, and masking was not attempted (four
subjects). Where this criterion was not met, additional
measurements of masked bone conduction were obtained
from 15 subjects (the others were unable to perform the
masking procedure). For the cleaned dataset in the remaining
17 subjects, the unmasked bone conduction was compared
with the air conduction in the better hearing ear.
Tympanometry was performed using either a GSI Tympstar
or an Amplivox Otowave 102 hand-held portable tympan-
ometer (both machines comply with the BSEN 60645 part 5
speciﬁcation for tympanometers and are calibrated to ISO
389 series). Individual ears (n ¼ 19) with ﬂat tympanograms
or markedly negative middle ear pressures (,150 daPa in
children, ,50 daPa in adults) were excluded from the
cleaned dataset.
Mouse strains
All work with mice complied with protocols approved by the
University of Utah Institutional Animal Care and Use Committee.
Fgfr3
P244R/þ mice backcrossed to four inbred backgrounds
(129S6, CBA/CaJ, C57BL/6 and BALB/c) were transferred
to the University of Utah and genotyped as described by
Twigg et al. (28). The auditory and histological studies
reported here were carried out on subjects derived from
48 Human Molecular Genetics, 2009, Vol. 18, No. 1heterozygous intercrosses of Muenke model animals in the
seventh to ninth backcross generation. Similar to the results
reported by Twigg et al., the penetrance of obvious craniofa-
cial malformations in Utah-bred homozygotes was 75% in
the C57BL/6 background, 64% in the 129S6 background and
36% in the CBA/Ca background. The only BALB/c homozy-
gote that was recovered was affected. The penetrance of
craniofacial malformations in heterozygotes on the C57BL/6,
129S6, CBA/Ca and BALB/c backgrounds was 11, 15, 0
and 5%, respectively.
Auditory rescue analyses were carried out on animals derived
from crossing BALB/c-Fgfr3
P244R/þ to Fgf8
þ/2 animals orig-
inally obtained from Dr Anne Moon and maintained on a mixed
genetic background (primarily C57BL/6, 129X1 and 129S1)
(46). Fgfr3
P244R/þ; Fgf8
þ/2 animals from the mixed genetic
background were crossed to C57BL/6-Fgf9
þ/2 animals obtained
from Dr. David Ornitz to generate animals of all possible
combinations of Fgfr3, Fgf8 and Fgf9 alleles (47).
Mouse ABR threshold measurements
To avoid the possibility of confounding age-related hearing loss
with Fgfr3
P244R-speciﬁc effects, all animals used for ABR
testing were 4–5 weeks old. Mice were anesthetized using
0.02 ml/g Avertin. ABR thresholds for click (1–16kHz,
47 ms duration, 29.3/s), 8, 16 and 32 kHz tone-pip stimuli
(3 ms duration, 29.3/s, Exact Blackman envelope) were deter-
mined using high-frequency transducers controlled and analysed
by SmartEP software (Intelligent Hearing Systems) as described
(48). This protocol was chosen to enable comparisons with the
mouse auditory screening project at The Jackson Laboratory
(http://hearingimpairment.jax.org/screening.html) as well as
with ABR tests of Spry2 and Fgfr3 null mice (8,11,14).
Testing was carried out blind with respect to genotype, but in
some cases,the genotypecouldbeinferred based oncraniofacial
phenotypes (28). ABR results were obtained from the following
numbers of inbred subjects: 129S6-Fgfr3
þ/þ, 19; 129S6-
Fgfr3
P244R/þ, 19; 129S6-Fgfr3
P244R/P244R,9 ;CBA/Ca-Fgfr3
þ/þ,
11; CBA/Ca-Fgfr3
P244R/þ, 12; CBA/Ca-Fgfr3
P244R/P244R,
13; BALB/c-Fgfr3
þ/þ, 12; BALB/c-Fgfr3
P244R/þ, 13; C57BL/
6-Fgfr3
þ/þ, 11; C57BL/6-Fgfr3
P244R/þ, 12; C57BL/6-
Fgfr3
P244R/P244R,1 3 .
Statistics
The ABR data were analysed for differences between geno-
types using a general linear model, controlling for strain back-
ground and stimuli. Differences between heterozygous or
homozygous and wild-type means were calculated by least
square means.
Inner ear histology and phalloidin staining of cochlear
epithelia
For histology, adult mice were perfused with 4% PFA in PBS,
the ears were removed and decalciﬁed in 0.1 M EDTA/2%
HCHO/25 mM HCl, then embedded in parafﬁn wax and sec-
tioned in the plane of the modiolus at 5–10 mm. Sections
were stained with haematoxylin and eosin.
For visualization of ﬁlamentous actin, cochleae were dis-
sected in ice-cold PBS, rinsed in PBS containing 0.01%
Triton X-100 (PBS/Triton) and then incubated for 15 min at
48C with Alexa 488-phalloidin (Invitrogen) diluted 1:1000 in
PBS/Triton. The labelled cochlea were rinsed in PBS/Triton
and mounted in FluoromountTM for observation.
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Supplementary Material is available at HMG Online.
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